Full access
Clinical and Research News
Published Online: 10 July 2013

Varenicline Shows Promise as Alcohol Abuse Treatment

Joan Arehart-TreichelAuthors Info & Affiliations
Publication: Psychiatric News
Volume 48, Number 14
https://doi.org/10.1176/appi.pn.2013.7a4
It appears that the smoking-cessation medication varenicline can also reduce alcohol use by people who are alcohol dependent.
A medication used to aid smoking cessation—varenicline (Chantix)—can also reduce alcohol dependence, according to a study published June 3 in the Journal of Addiction Medicine.
The study was conducted by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Clinical Investigations Group—a multicenter team of researchers.
Two hundred men and women meeting criteria for alcohol dependence were recruited across five clinical sites. The subjects received varenicline or a placebo for 13 weeks.
Data showed that the varenicline group consumed significantly less alcohol and experienced significantly less alcohol craving than did the placebo group. Moreover, the average treatment effect of varenicline on alcohol use was similar for smokers and nonsmokers. Varenicline was also well tolerated. The most common side effects were nausea, abnormal dreams, and constipation, and those effects were generally mild, the researchers noted.
Thus, varenicline is “a potentially viable option for the treatment of alcohol dependence,” the researchers concluded in their paper.
“This is an encouraging development in our effort to expand and improve treatment options for people with alcohol dependence,” Kenneth Warren, Ph.D., acting director of NIAAA, said in an accompanying press statement. “Current medications for alcohol dependence are effective for some, but not all, patients. New medications are needed to provide effective therapy to a broader spectrum of alcohol-dependent individuals.”
“Drinking and smoking often co-occur, and given their genetic and neurochemical similarities, it is perhaps not surprising that a smoking cessation treatment might serve to treat alcohol problems,” Raye Litten, Ph.D., noted in the same statement. Litten, associate director of the NIAAA Division of Treatment and Recovery Research, was the lead investigator in the study.
Varenicline is a partial nicotinic acetylcholine agonist approved by the Food and Drug Administration for smoking cessation in 2006. ■
An abstract of “A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence” is posted at http://journals.lww.com/journaladdictionmedicine.

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 48 • Number 14 • July 6, 2013 – July 19, 2013
Pages: 1

History

Published online: 10 July 2013
Published in print: July 6, 2013 – July 19, 2013

Keywords

  1. alcohol
  2. a drug for alcohol dependence
  3. varenicline
  4. Chantix

Authors

Affiliations

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share